I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients

• Sarvarinder K. Gill,
• Rashmi Unawane,
• Shuqi Wang,
• Jaeil Ahn,
• Adolfo Aleman,
• David S. Siegel,
• David H. Vesole,
• Harsh Parmar,
• Pooja Phull,
• Noa Biran

Affiliations

Sarvarinder K. Gill

Department of Medicine, Hackensack Meridian School of Medicine, Hackensack University Medical Center

Rashmi Unawane

Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack University Medical Center

Shuqi Wang

Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University

Jaeil Ahn

Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University

Adolfo Aleman

Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack University Medical Center

David S. Siegel

Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack University Medical Center

David H. Vesole

Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack University Medical Center

Harsh Parmar

Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack University Medical Center

Pooja Phull

Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack University Medical Center

Noa Biran

Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack University Medical Center